Błoński J Z, Warzocha K
II Klinika Chorób Wewnetrznych Instytutu Medycyny Wewnetrznej Akademii Medycznej w Lodzi.
Postepy Hig Med Dosw. 1994;48(6):701-28.
In this article we present new immunotherapy modalities in clinical oncology. We review various forms of immunotherapy as well as their clinical effectiveness. At present, effects of cellular adoptive therapy are not satisfying. However, much hope is provided by monoclonal antibodies against tumor-associated antigens. Efficacy of monoclonal antibodies may be increased by their conjugation with various cytotoxic molecules. The number of indications for clinical applications of recombinant cytokines, mainly interferons, IL-2 and CSFs is growing. Genetic engineering creates new possibilities also in this case; modification of cytokine molecules as well as production of fusion proteins, i.e. design of quite novel protein structures that combine the function of two or more cytokines. It is very likely that antineoplastic immunotherapy might become, as is the case with gene therapy, one of future powerful tool against cancer.
在本文中，我们介绍了临床肿瘤学中的新免疫治疗方法。我们回顾了各种形式的免疫治疗及其临床疗效。目前，细胞过继性疗法的效果并不令人满意。然而，针对肿瘤相关抗原的单克隆抗体带来了很大希望。单克隆抗体与各种细胞毒性分子结合可提高其疗效。重组细胞因子，主要是干扰素、白细胞介素-2和集落刺激因子的临床应用适应证数量正在增加。基因工程在这种情况下也创造了新的可能性；细胞因子分子的修饰以及融合蛋白的产生，即设计结合两种或更多种细胞因子功能的全新蛋白质结构。抗肿瘤免疫治疗很可能会像基因治疗一样，成为未来对抗癌症的强大工具之一。
